Literature DB >> 2438581

Muscarinic M1 receptors in the lateral septal area mediate cardiovascular responses to cholinergic agonists and bradykinin: supersensitivity induced by chronic treatment with atropine.

A Scheucher, C J Pirola, M S Balda, S M Dabsys, A L Alvarez, S Finkielman, V E Nahmod.   

Abstract

The infusion of pilocarpine, acetylcholine, bradykinin and the selective M1 muscarinic agonist McNeil-A-343 into the lateral septal area produced a dose-dependent increase of arterial blood pressure and heart rate. The M1 muscarinic agonist carbamylcholine that causes a rise in arterial blood pressure when injected into the anterior lateral ventricles did not produce any cardiovascular effects when infused into the lateral septal area. Chronic treatment with atropine induced supersensitivity to the muscarinic agonists and a significant increase in the number of muscarinic receptors. In this study bradykinin failed to produce any significant change in cardiovascular activity. Pirenzepine, a M1 muscarinic blocking agent, inhibited completely the effect of both muscarinic agonists and bradykinin on cardiovascular activity. In fact, in vitro studies shows that the displacement of the binding of [3H]QNB by pirenzepine is compatible with the presence of the M1 subtype of muscarinic receptor in the lateral septal area, where it may play a major role on cardiovascular regulation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2438581     DOI: 10.1016/0028-3908(87)90207-3

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  2 in total

1.  Cardiovascular effects of the intracerebroventricular injection of adrenomedullin: roles of the peripheral vasopressin and central cholinergic systems.

Authors:  B Cam-Etoz; N Isbil-Buyukcoskun; K Ozluk
Journal:  Braz J Med Biol Res       Date:  2012-03-01       Impact factor: 2.590

2.  A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M1 receptor agonist HTL0018318 in patients with mild-to-moderate Alzheimer's disease.

Authors:  Pradeep J Nathan; S Babli Millais; Alex Godwood; Odile Dewit; David M Cross; Janet Liptrot; Bharat Ruparelia; Stephen Paul Jones; Geor Bakker; Paul T Maruff; Gregory A Light; Alastair J H Brown; Malcolm Peter Weir; Miles Congreve; Tim Tasker
Journal:  Alzheimers Dement (N Y)       Date:  2022-02-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.